Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Exploratory Clinical Study of the Safety and Efficacy of NKG2D Chimeric Antigen Receptor NK Cell Injections for the Treatment of Efractory Recurrent Multiple Myeloma

NCT06379451 is registered in ClinicalTrials.gov with Changzhou No.2 People's Hospital as lead sponsor.

NCT NCT06379451
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06379451 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Exploratory Clinical Study of the Safety and Efficacy of NKG2D Chimeric Antigen Receptor NK Cell Injections for the Treatment of Efractory Recurrent Multiple Myeloma
Lead sponsor
Changzhou No.2 People's Hospital
Phase
Phase 1
Overall status
Unknown status
Start date
April 18, 2024
Completion date
December 31, 2025
Enrollment
9 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

multiple myeloma